Johannes Kurt Schultz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Johannes Kurt Schultz has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Pamela Buchwald
Department of Surgery, Skåne University Hospital, Malmö, Sweden
5 shared publications - Abbas Chabok
Centre for Clinical Research Västmanland, Uppsala University, 72189 Västerås, Sweden
4 shared publications Jūratė Šaltytė Benth
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3 shared publicationsTom Øresland
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3 shared publications- Amjad Parvaiz
Colorectal Surgery, Champalimaud Foundation, Lisbon, Portugal
2 shared publications Andreas Linz
Dresden, DE
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 3008-3019
Small Bowel Cancer: Implications of Preoperative Work‐Up on Surgical Strategy
Background: Small bowel cancers comprise a heterogeneous group of malignancies, making diagnosis and treatment challenging. This study aimed to evaluate the ability of preoperative diagnostic work‐up to predict clinical and histopathological findings, facilitate subgroup identification, and support tailored, individualized surgical strategies. Methods: This retrospective single‐center analysis included all patients operated 2015–2024 for suspected small bowel cancer at a tertiary referral center. Preoperative assessments—including diagnostic evaluation of tumor type, disease extent, and anatomical localization—were compared to intraoperative findings and final histopathological results. Results: Of 187 operations, 59 (32%) were right colectomies, 50 (27%) robotic/laparoscopic procedures and 36 (19%) emergencies. Preoperative symptoms were present in 156 (83%) patients. CT scans were performed in 184 (98%), somatostatin receptor imaging (SRI) in 120 (64%), endoscopy in 92 (49%), and biopsy in 74 (40%). Small intestinal neuroendocrine tumors (siNET) were found in 108 (58%) patients, carcinomas in 24 (13%), metastatic tumors in 17 (9%), gastrointestinal stromal tumors in 13 (7%), benign lesions in 13 (7%), lymphomas in 8 (4%), and desmoid tumors in 4 (2%). The preoperative tentative tumor entity was correct in 118 (63%). CT sensitivities for mesenteric and peritoneal metastases were 65% and 9%, respectively. SRI was positive in 83/92 siNET and 6/28 non‐NET. Mesenteric metastases were found in 99 (95%) siNET patients. SRI failed to identify mesenteric dissemination in 24 (27%) siNET patients. Among patients with siNET, 18 (17%) had liver metastases and 18 (17%) had peritoneal metastases. SiNET multifocality was associated with distant metastatic status ( p < 0.001). Pathologists found 313 luminal siNET, 17 tumors were missed by intraoperative palpation, 51 by SRI and 156 by CT. All siNET were in the ileum. Terminal compared to middle/upper ileum siNET were more often solitary (39/42 [93%] vs. 31/60 [52%]; p < 0.001) and had less often advanced mesenteric disease (N2) (9/44 [20%] vs. 31/58 [53%]; p < 0.001). Conclusions: Preoperative work‐up of small bowel cancer is often inaccurate, particularly when it comes to identification of bowel tumors and metastases. Intraoperative palpation of the bowel and its mesentery and inspection of the peritoneum remain essential to facilitate an adaptive surgical strategy.
- 3 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 3008-3019
Open AccessSmall Bowel Cancer: Implications of Preoperative Work‐Up on Surgical Strategy
Background: Small bowel cancers comprise a heterogeneous group of malignancies, making diagnosis and treatment challenging. This study aimed to evaluate the ability of preoperative diagnostic work‐up to predict clinical and histopathological findings, facilitate subgroup identification, and support tailored, individualized surgical strategies. Methods: This retrospective single‐center analysis included all patients operated 2015–2024 for suspected small bowel cancer at a tertiary referral center. Preoperative assessments—including diagnostic evaluation of tumor type, disease extent, and anatomical localization—were compared to intraoperative findings and final histopathological results. Results: Of 187 operations, 59 (32%) were right colectomies, 50 (27%) robotic/laparoscopic procedures and 36 (19%) emergencies. Preoperative symptoms were present in 156 (83%) patients. CT scans were performed in 184 (98%), somatostatin receptor imaging (SRI) in 120 (64%), endoscopy in 92 (49%), and biopsy in 74 (40%). Small intestinal neuroendocrine tumors (siNET) were found in 108 (58%) patients, carcinomas in 24 (13%), metastatic tumors in 17 (9%), gastrointestinal stromal tumors in 13 (7%), benign lesions in 13 (7%), lymphomas in 8 (4%), and desmoid tumors in 4 (2%). The preoperative tentative tumor entity was correct in 118 (63%). CT sensitivities for mesenteric and peritoneal metastases were 65% and 9%, respectively. SRI was positive in 83/92 siNET and 6/28 non‐NET. Mesenteric metastases were found in 99 (95%) siNET patients. SRI failed to identify mesenteric dissemination in 24 (27%) siNET patients. Among patients with siNET, 18 (17%) had liver metastases and 18 (17%) had peritoneal metastases. SiNET multifocality was associated with distant metastatic status ( p < 0.001). Pathologists found 313 luminal siNET, 17 tumors were missed by intraoperative palpation, 51 by SRI and 156 by CT. All siNET were in the ileum. Terminal compared to middle/upper ileum siNET were more often solitary (39/42 [93%] vs. 31/60 [52%]; p < 0.001) and had less often advanced mesenteric disease (N2) (9/44 [20%] vs. 31/58 [53%]; p < 0.001). Conclusions: Preoperative work‐up of small bowel cancer is often inaccurate, particularly when it comes to identification of bowel tumors and metastases. Intraoperative palpation of the bowel and its mesentery and inspection of the peritoneum remain essential to facilitate an adaptive surgical strategy.
- Open Access
- 2 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2996-3007
Extended D3 Mesenterectomy in Small Bowel Cancer Treatment: Feasibility and Importance for Staging. First Results of a Prospective Clinical Trial
Background: There is no consensus on surgical techniques in small bowel cancer, particularly regarding the extent of lymph node dissection and strategic choices according to tumor localization and histological type. Clearance of central lymph node metastases can be challenging, especially when small intestinal neuroendocrine tumor (siNET) metastases give rise to fibrosis and desmoplasia around the cranial parts of the superior mesenteric vessels. The aim of this study was to assess the feasibility and staging implications of new techniques of central (D3) lymphadenectomy. Material and Methods: The operative techniques in this prospective small bowel cancer cohort entailed central (D3) removal of all mesenteric tissue anterior and posterior to the superior mesenteric vessels up to the root of the mesentery. Preoperative 3D mapping of the vascular anatomy was performed to facilitate personalized surgery. A new resection classification was developed, based on bowel and mesentery involvement. Results: Among the 86 patients included, D3 lymphadenectomy was performed in 74 (86%). Small bowel resection was done in 40 (54%), and ileocecal or ileocolic resection in 34 (46%). There were five (7%) reoperations (two (3%) anastomotic leaks) and no 30‐day mortality. At histopathology, 60 siNET (81%), 5 small bowel carcinomas, 3 metastases of other origin, 1 benign lesion, 3 lymphomas, and 2 gastrointestinal stromal tumors (GIST) were diagnosed. Lymph node count of 71 patients (one benign, two lymphomas not counted) showed mesenteric lymph node metastases in 62 (87%) (median lymph node yield 33). Metastases to the D3 volume were found in 31 (44%) (median D3 lymph node yield 13). In the siNET‐group, 28/60 (47%) had D3 metastases, suggested in standard preoperative investigations in 12 (43%). Of all positive siNET lymph nodes, 173/509 (34%) were localized in the D3 volume. Upper/middle ileal siNET were D3 positive in 19/29 (66%) versus in 9/31 (29%) of terminal ileal siNET. All patients had mesenterial R0 resections. Conclusions: Central (D3) small bowel mesenterectomy can be performed with radicality and safety. The high proportion of central metastases that would remain in situ after traditional, less extensive (D2) surgery underlines the potential importance of D3 mesenterectomy for accurate staging and locoregional disease control. Subgroup analyses suggested differences in mesenteric dissemination between terminal ileal and more proximal small intestinal tumors.
- 2 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2996-3007
Open AccessExtended D3 Mesenterectomy in Small Bowel Cancer Treatment: Feasibility and Importance for Staging. First Results of a Prospective Clinical Trial
Background: There is no consensus on surgical techniques in small bowel cancer, particularly regarding the extent of lymph node dissection and strategic choices according to tumor localization and histological type. Clearance of central lymph node metastases can be challenging, especially when small intestinal neuroendocrine tumor (siNET) metastases give rise to fibrosis and desmoplasia around the cranial parts of the superior mesenteric vessels. The aim of this study was to assess the feasibility and staging implications of new techniques of central (D3) lymphadenectomy. Material and Methods: The operative techniques in this prospective small bowel cancer cohort entailed central (D3) removal of all mesenteric tissue anterior and posterior to the superior mesenteric vessels up to the root of the mesentery. Preoperative 3D mapping of the vascular anatomy was performed to facilitate personalized surgery. A new resection classification was developed, based on bowel and mesentery involvement. Results: Among the 86 patients included, D3 lymphadenectomy was performed in 74 (86%). Small bowel resection was done in 40 (54%), and ileocecal or ileocolic resection in 34 (46%). There were five (7%) reoperations (two (3%) anastomotic leaks) and no 30‐day mortality. At histopathology, 60 siNET (81%), 5 small bowel carcinomas, 3 metastases of other origin, 1 benign lesion, 3 lymphomas, and 2 gastrointestinal stromal tumors (GIST) were diagnosed. Lymph node count of 71 patients (one benign, two lymphomas not counted) showed mesenteric lymph node metastases in 62 (87%) (median lymph node yield 33). Metastases to the D3 volume were found in 31 (44%) (median D3 lymph node yield 13). In the siNET‐group, 28/60 (47%) had D3 metastases, suggested in standard preoperative investigations in 12 (43%). Of all positive siNET lymph nodes, 173/509 (34%) were localized in the D3 volume. Upper/middle ileal siNET were D3 positive in 19/29 (66%) versus in 9/31 (29%) of terminal ileal siNET. All patients had mesenterial R0 resections. Conclusions: Central (D3) small bowel mesenterectomy can be performed with radicality and safety. The high proportion of central metastases that would remain in situ after traditional, less extensive (D2) surgery underlines the potential importance of D3 mesenterectomy for accurate staging and locoregional disease control. Subgroup analyses suggested differences in mesenteric dissemination between terminal ileal and more proximal small intestinal tumors.
- Open Access
- 20 July 2026
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 115 (3) , 364-382
Treatment of localized rectal cancer in the Nordic countries—comparison of Nordic to Dutch, ESMO, and NCCN guidelines
Background: Rectal cancer treatment in Nordic countries has traditionally differed, especially regarding neoadjuvant treatment. The aim of this review is to give an overview of the current rectal cancer guidelines in the Nordics and compare these to international guidelines. Methods: Oncologists and colorectal surgeons from the Nordic countries (Denmark, Finland, Norway, and Sweden) and the Netherlands were invited to participate in this narrative review. Two consensus meetings were held to agree on the content. All authors provided recommendations from their national guidelines. In addition, recommendations from the European Society of Medical Oncology (ESMO) and from the US National Comprehensive Cancer Network (NCCN) guidelines were extracted. Results: Several differences between the included guidelines were identified. The radiological “sigmoid take-off” definition for the upper margin of the rectum has been adapted in Denmark and the Netherlands, whereas the other guidelines rely on distance from the anal verge on rigid sigmoidoscopy. Indications for direct surgery vary considerably, where the NCCN guidelines recommend more aggressive neoadjuvant treatment, primarily total neoadjuvant therapy (TNT), the Nordic and European guidelines open for direct surgery more often, and reserve especially TNT for high-risk cases. European countries more often recommend short-course radiotherapy, whereas NCCN maintains chemoradiotherapy as the mainstay. Whereas intentional and opportunistic organ preservation is an established part of the Dutch, NCCN, and ESMO guidelines, its use is mostly restricted to clinical trials in the Nordics. The Nordics and the Netherlands are restrictive in terms of adjuvant treatment, which is frequently recommended in ESMO and NCCN. Whereas neoadjuvant immunotherapy is recommended for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) rectal cancer in NCCN, this use is off-label in Europe and not routinely recommended. Conclusion: Although all guidelines rely on the same evidence, there are considerable differences, especially in the indications and type of oncologic treatment, both in the neoadjuvant and in the adjuvant setting.
- 20 July 2026
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 115 (3) , 364-382
Open AccessTreatment of localized rectal cancer in the Nordic countries—comparison of Nordic to Dutch, ESMO, and NCCN guidelines
Background: Rectal cancer treatment in Nordic countries has traditionally differed, especially regarding neoadjuvant treatment. The aim of this review is to give an overview of the current rectal cancer guidelines in the Nordics and compare these to international guidelines. Methods: Oncologists and colorectal surgeons from the Nordic countries (Denmark, Finland, Norway, and Sweden) and the Netherlands were invited to participate in this narrative review. Two consensus meetings were held to agree on the content. All authors provided recommendations from their national guidelines. In addition, recommendations from the European Society of Medical Oncology (ESMO) and from the US National Comprehensive Cancer Network (NCCN) guidelines were extracted. Results: Several differences between the included guidelines were identified. The radiological “sigmoid take-off” definition for the upper margin of the rectum has been adapted in Denmark and the Netherlands, whereas the other guidelines rely on distance from the anal verge on rigid sigmoidoscopy. Indications for direct surgery vary considerably, where the NCCN guidelines recommend more aggressive neoadjuvant treatment, primarily total neoadjuvant therapy (TNT), the Nordic and European guidelines open for direct surgery more often, and reserve especially TNT for high-risk cases. European countries more often recommend short-course radiotherapy, whereas NCCN maintains chemoradiotherapy as the mainstay. Whereas intentional and opportunistic organ preservation is an established part of the Dutch, NCCN, and ESMO guidelines, its use is mostly restricted to clinical trials in the Nordics. The Nordics and the Netherlands are restrictive in terms of adjuvant treatment, which is frequently recommended in ESMO and NCCN. Whereas neoadjuvant immunotherapy is recommended for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) rectal cancer in NCCN, this use is off-label in Europe and not routinely recommended. Conclusion: Although all guidelines rely on the same evidence, there are considerable differences, especially in the indications and type of oncologic treatment, both in the neoadjuvant and in the adjuvant setting.
- Open Access
- 15 February 2026
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 115 (2) , 137-146
Accuracy and reliability of preoperative CT in perforated diverticulitis: Post hoc secondary analysis from the SCANDIV trial
Background and Aims: Undetected cancers and fecal contamination in perforated diverticulitis may lead to failure of laparoscopic lavage. This study aimed to evaluate the diagnostic accuracy of preoperative computed tomography (CT) examinations and the interobserver agreement for detecting colonic malignancy and fecal contamination in patients with perforated diverticulitis. Methods: This study included 198 patients with suspected perforated diverticulitis from the SCANDIV trial, randomized to laparoscopic lavage or primary resection. CT examinations of all patients were independently reviewed by two specialists in abdominal radiology, and features of fecal contamination and colonic malignancy were registered and compared to the surgical reports. Results: At surgery, fecal contamination was described in 33 patients and was diagnosed on CT in 7 of those by both radiologists (sensitivity = 21%, specificity = 96%, positive predictive value (PPV) = 50%, and negative predictive value (NPV) = 86%) and in 25 patients by at least one of the radiologists (sensitivity = 76%, specificity = 63%, PPV = 29%, and NPV = 93%). Interobserver agreement between radiologists was 64% for fecal contamination (kappa = 0.18, SE = 0.05; p < 0.001). In 7 of 12 patients who turned out to have colon cancer, this was suspected at CT by at least one radiologist (sensitivity = 58%, specificity = 91%, PPV = 29%, NPV = 97%). Interobserver agreement between radiologists for suspected colonic malignancy was 92% (kappa = 0.46; SE = 0.12; p < 0.001). Conclusion: In this selected cohort of patients with suspected perforated diverticulitis, re-evaluation of CT scans proved unreliable for detecting malignancies and fecal contamination. This suggests that preoperative CT cannot replace follow-up colonoscopy or colonography following laparoscopic lavage.
- 15 February 2026
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 115 (2) , 137-146
Open AccessAccuracy and reliability of preoperative CT in perforated diverticulitis: Post hoc secondary analysis from the SCANDIV trial
Background and Aims: Undetected cancers and fecal contamination in perforated diverticulitis may lead to failure of laparoscopic lavage. This study aimed to evaluate the diagnostic accuracy of preoperative computed tomography (CT) examinations and the interobserver agreement for detecting colonic malignancy and fecal contamination in patients with perforated diverticulitis. Methods: This study included 198 patients with suspected perforated diverticulitis from the SCANDIV trial, randomized to laparoscopic lavage or primary resection. CT examinations of all patients were independently reviewed by two specialists in abdominal radiology, and features of fecal contamination and colonic malignancy were registered and compared to the surgical reports. Results: At surgery, fecal contamination was described in 33 patients and was diagnosed on CT in 7 of those by both radiologists (sensitivity = 21%, specificity = 96%, positive predictive value (PPV) = 50%, and negative predictive value (NPV) = 86%) and in 25 patients by at least one of the radiologists (sensitivity = 76%, specificity = 63%, PPV = 29%, and NPV = 93%). Interobserver agreement between radiologists was 64% for fecal contamination (kappa = 0.18, SE = 0.05; p < 0.001). In 7 of 12 patients who turned out to have colon cancer, this was suspected at CT by at least one radiologist (sensitivity = 58%, specificity = 91%, PPV = 29%, NPV = 97%). Interobserver agreement between radiologists for suspected colonic malignancy was 92% (kappa = 0.46; SE = 0.12; p < 0.001). Conclusion: In this selected cohort of patients with suspected perforated diverticulitis, re-evaluation of CT scans proved unreliable for detecting malignancies and fecal contamination. This suggests that preoperative CT cannot replace follow-up colonoscopy or colonography following laparoscopic lavage.
- Open Access
- 6 June 2025
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 114 (3) , 381-389
Changing paradigms in the management of complicated diverticulitis
Complicated colonic diverticulitis remains a frequent cause of hospital admissions in Western countries, associated with significant morbidity and health care utilization. Complications include abscess formation, perforation, sepsis, fistulas, and colonic stenosis, which may be present at initial presentation or develop during the disease course. Approximately 10%–20% of hospitalized diverticulitis cases are classified as complicated. Over recent decades, the management of this condition has undergone a paradigm shift—from routine surgical intervention to more individualized, evidence-based strategies emphasizing conservative treatment where appropriate. This review provides a comprehensive, clinically oriented summary of current diagnostic approaches, including the role of cross-sectional imaging, as well as non-operative and operative treatment options. It also outlines recommendations for follow-up, including indications for colonoscopy, and discusses ongoing controversies and future directions in the management of complicated diverticulitis.
- 6 June 2025
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 114 (3) , 381-389
Open AccessChanging paradigms in the management of complicated diverticulitis
Complicated colonic diverticulitis remains a frequent cause of hospital admissions in Western countries, associated with significant morbidity and health care utilization. Complications include abscess formation, perforation, sepsis, fistulas, and colonic stenosis, which may be present at initial presentation or develop during the disease course. Approximately 10%–20% of hospitalized diverticulitis cases are classified as complicated. Over recent decades, the management of this condition has undergone a paradigm shift—from routine surgical intervention to more individualized, evidence-based strategies emphasizing conservative treatment where appropriate. This review provides a comprehensive, clinically oriented summary of current diagnostic approaches, including the role of cross-sectional imaging, as well as non-operative and operative treatment options. It also outlines recommendations for follow-up, including indications for colonoscopy, and discusses ongoing controversies and future directions in the management of complicated diverticulitis.
- Open Access
- 30 January 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (2) , e70009
SELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma‐free survival without major LARS following total mesorectal excision
Aim: Accumulated data suggest that routine use of defunctioning stoma in low anterior resection for rectal cancer may cause kidney injury, bowel dysfunction and a higher risk of permanent stomas. We aim to study whether avoidance of a diverting stoma in selected patients is safe and reduces adverse consequences.Methods: SELSA is a multicentre international prospective observational study nesting an open‐label randomized clinical trial. All patients with primary rectal cancer planned for low anterior resection are eligible. Patients operated with curative intent, aged <80 years, with an American Society of Anaesthesiologists' fitness grade I or II, and a low predicted risk of anastomotic leakage are eligible to 1:1 randomization between no defunctioning stoma (experimental arm) or a defunctioning stoma (control arm). The primary outcome is the composite measure of 2‐year stoma‐free survival without major low anterior resection syndrome (LARS). Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma‐related complications, quality of life measures, LARS score, and permanent stoma rate. To be able to state superiority of any study arm regarding the main outcome, with 90% statistical power and assuming 25% attrition, we aim to enrol 212 patients. Patient inclusion will commence in the autumn of 2024.Conclusion: The SELSA study is investigating a tailored approach to defunctioning stoma use in low anterior resection for rectal cancer in relation to the risk of anastomotic leakage. Our hypothesis is that long‐term effects will favour the selective approach, enabling some patients to avoid a defunctioning stoma.Trial registration: Swedish Ethical Review Authority approval (2023–04347‐01, 2024–02418‐02 and 2024–03622‐02), Regional Ethics Committee Denmark (H‐24014463), and ClinicalTrials.gov (NCT06214988).
- 30 January 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (2) , e70009
Open AccessSELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma‐free survival without major LARS following total mesorectal excision
Aim: Accumulated data suggest that routine use of defunctioning stoma in low anterior resection for rectal cancer may cause kidney injury, bowel dysfunction and a higher risk of permanent stomas. We aim to study whether avoidance of a diverting stoma in selected patients is safe and reduces adverse consequences.Methods: SELSA is a multicentre international prospective observational study nesting an open‐label randomized clinical trial. All patients with primary rectal cancer planned for low anterior resection are eligible. Patients operated with curative intent, aged <80 years, with an American Society of Anaesthesiologists' fitness grade I or II, and a low predicted risk of anastomotic leakage are eligible to 1:1 randomization between no defunctioning stoma (experimental arm) or a defunctioning stoma (control arm). The primary outcome is the composite measure of 2‐year stoma‐free survival without major low anterior resection syndrome (LARS). Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma‐related complications, quality of life measures, LARS score, and permanent stoma rate. To be able to state superiority of any study arm regarding the main outcome, with 90% statistical power and assuming 25% attrition, we aim to enrol 212 patients. Patient inclusion will commence in the autumn of 2024.Conclusion: The SELSA study is investigating a tailored approach to defunctioning stoma use in low anterior resection for rectal cancer in relation to the risk of anastomotic leakage. Our hypothesis is that long‐term effects will favour the selective approach, enabling some patients to avoid a defunctioning stoma.Trial registration: Swedish Ethical Review Authority approval (2023–04347‐01, 2024–02418‐02 and 2024–03622‐02), Regional Ethics Committee Denmark (H‐24014463), and ClinicalTrials.gov (NCT06214988).
- Open Access
- 3 September 2024
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 8 (5)
Effect of radiotherapy on long-term quality of life in recurrence-free rectal cancer survivors (LaTE study): nationwide inverse probability of treatment-weighted registry-based cohort study and survey
Radiotherapy reduces local recurrence in locally advanced rectal cancer, but may cause harm in patients who do not experience recurrence. The aim was to investigate the impact of radiotherapy on long-term quality of life after curative treatment for rectal cancer, i.e. in patients without a recurrence during the follow-up. All patients operated on for rectal cancer in Norway under 75 years of age between 30 September 2007 and 1 October 2020 were identified using the Cancer Registry of Norway. Exclusion criteria were distant metastasis, recurrence and dementia. The primary outcome measure was the Gastrointestinal Quality of Life Index. Secondary outcome measures included the 36-item Short Form Survey. Inverse probability weights based on a multiple logistic regression model were used to balance prechosen covariates between the radiotherapy and no radiotherapy groups when assessing differences in outcomes. Of 5014 invited patients, 2142 (43%) eligible patients answered the questionnaires. Of these 762 (36%) were treated with neoadjuvant radiotherapy plus surgery and 1380 (64%) with surgery alone. The mean follow-up time was 6.4 and 7.4 years respectively. After propensity score matching, the Gastrointestinal Quality of Life Index differed significantly between irradiated and non-irradiated patients ((mean(s.d.), mean score 103.8(19.4) versus 110.8(19.6) respectively, mean difference: −6.96 (95% c.i. −8.72 to −5.19); P < 0.001). Among patients without a stoma the mean difference was −8.1 points, whereas it was −5.7 for patients with a stoma. The radiotherapy group also scored significantly lower in 7 of 8 36-item Short Form Survey domains compared with the surgery alone group. Long-term quality of life was significantly lower in patients without a recurrence during the follow-up who received radiotherapy compared with patients who did not. These findings warrant a critical re-evaluation of the use of radiotherapy both in traditional neoadjuvant treatment and in modern organ-preserving treatment regimens.
- 3 September 2024
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 8 (5)
Open AccessEffect of radiotherapy on long-term quality of life in recurrence-free rectal cancer survivors (LaTE study): nationwide inverse probability of treatment-weighted registry-based cohort study and survey
Radiotherapy reduces local recurrence in locally advanced rectal cancer, but may cause harm in patients who do not experience recurrence. The aim was to investigate the impact of radiotherapy on long-term quality of life after curative treatment for rectal cancer, i.e. in patients without a recurrence during the follow-up. All patients operated on for rectal cancer in Norway under 75 years of age between 30 September 2007 and 1 October 2020 were identified using the Cancer Registry of Norway. Exclusion criteria were distant metastasis, recurrence and dementia. The primary outcome measure was the Gastrointestinal Quality of Life Index. Secondary outcome measures included the 36-item Short Form Survey. Inverse probability weights based on a multiple logistic regression model were used to balance prechosen covariates between the radiotherapy and no radiotherapy groups when assessing differences in outcomes. Of 5014 invited patients, 2142 (43%) eligible patients answered the questionnaires. Of these 762 (36%) were treated with neoadjuvant radiotherapy plus surgery and 1380 (64%) with surgery alone. The mean follow-up time was 6.4 and 7.4 years respectively. After propensity score matching, the Gastrointestinal Quality of Life Index differed significantly between irradiated and non-irradiated patients ((mean(s.d.), mean score 103.8(19.4) versus 110.8(19.6) respectively, mean difference: −6.96 (95% c.i. −8.72 to −5.19); P < 0.001). Among patients without a stoma the mean difference was −8.1 points, whereas it was −5.7 for patients with a stoma. The radiotherapy group also scored significantly lower in 7 of 8 36-item Short Form Survey domains compared with the surgery alone group. Long-term quality of life was significantly lower in patients without a recurrence during the follow-up who received radiotherapy compared with patients who did not. These findings warrant a critical re-evaluation of the use of radiotherapy both in traditional neoadjuvant treatment and in modern organ-preserving treatment regimens.
- Open Access
- 4 March 2024
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 113 (1) , 60-61
Stoma formation: An underestimated challenge in emergency surgery
- 4 March 2024
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 113 (1) , 60-61
Open AccessStoma formation: An underestimated challenge in emergency surgery
- Open Access
- 30 November 2023
- Published by Wiley in Colorectal Disease
- Vol. 26 (1) , 22-33
Chemotherapy reduces long‐term quality of life in recurrence‐free colon cancer survivors (LaTE study)—a nationwide inverse probability of treatment‐weighted registry‐based cohort study and survey
Aim: Stage III colon cancer is routinely treated with adjuvant chemotherapy, which causes significant short‐term morbidity. Its effect on long‐term quality of life (QoL) is poorly investigated. The aim of this study was to investigate long‐term QoL after curative treatment for colon cancer and explore the impact of chemotherapy on general and disease‐specific QoL.Method: All patients aged under 75 years operated on for colon cancer between 30 September 2007 and 1 October 2019 were identified by the Cancer Registry of Norway. Exclusion criteria were distant metastasis, recurrence, dementia and rectal/rectosigmoid cancer operation. The primary outcome measure was Gastrointestinal Quality of Life Index (GIQLI). Secondary outcome measures included the Short Form Health Survey (SF‐36). To achieve balanced groups when assessing differences in outcome measures the analyses were weighted by inverse probability weights based on a multiple logistic regression model with prechosen confounders.Results: A total of 8627 patients were invited and 3109 responded (36% response rate). After exclusions 3025 patients were included, of whom 1148 (38%) had received adjuvant chemotherapy and 1877 (62%) had surgery alone, with mean follow‐up of 75.5 versus 74.5 months, respectively. The GIQLI differed significantly between the groups [mean 111.0 (SD 18.4) vs. 115.6 (SD 17.8), respectively; mean difference: −4.6 (95% CI −5.9; −3.2); p < 0.001]. Those with the highest neurotoxicity exhibited the lowest GIQLI. The adjuvant chemotherapy group scored significantly lower in six of eight SF‐36 domains compared with the surgery alone group. The main differences were found in social, physical and emotional function.Conclusion: Long‐term QoL was significantly lower in patients who received adjuvant chemotherapy than in patients who did not. Neurotoxicity was closely related to reduced QoL in these patients. The low response rate limits the generalizability of the results.
- 30 November 2023
- Published by Wiley in Colorectal Disease
- Vol. 26 (1) , 22-33
Open AccessChemotherapy reduces long‐term quality of life in recurrence‐free colon cancer survivors (LaTE study)—a nationwide inverse probability of treatment‐weighted registry‐based cohort study and survey
Aim: Stage III colon cancer is routinely treated with adjuvant chemotherapy, which causes significant short‐term morbidity. Its effect on long‐term quality of life (QoL) is poorly investigated. The aim of this study was to investigate long‐term QoL after curative treatment for colon cancer and explore the impact of chemotherapy on general and disease‐specific QoL.Method: All patients aged under 75 years operated on for colon cancer between 30 September 2007 and 1 October 2019 were identified by the Cancer Registry of Norway. Exclusion criteria were distant metastasis, recurrence, dementia and rectal/rectosigmoid cancer operation. The primary outcome measure was Gastrointestinal Quality of Life Index (GIQLI). Secondary outcome measures included the Short Form Health Survey (SF‐36). To achieve balanced groups when assessing differences in outcome measures the analyses were weighted by inverse probability weights based on a multiple logistic regression model with prechosen confounders.Results: A total of 8627 patients were invited and 3109 responded (36% response rate). After exclusions 3025 patients were included, of whom 1148 (38%) had received adjuvant chemotherapy and 1877 (62%) had surgery alone, with mean follow‐up of 75.5 versus 74.5 months, respectively. The GIQLI differed significantly between the groups [mean 111.0 (SD 18.4) vs. 115.6 (SD 17.8), respectively; mean difference: −4.6 (95% CI −5.9; −3.2); p < 0.001]. Those with the highest neurotoxicity exhibited the lowest GIQLI. The adjuvant chemotherapy group scored significantly lower in six of eight SF‐36 domains compared with the surgery alone group. The main differences were found in social, physical and emotional function.Conclusion: Long‐term QoL was significantly lower in patients who received adjuvant chemotherapy than in patients who did not. Neurotoxicity was closely related to reduced QoL in these patients. The low response rate limits the generalizability of the results.
- 9 November 2023
- Published by Springer Nature
- p. 1013-1029
Management of Fecal Incontinence, Constipation, and Rectal Prolapse
- 9 November 2023
- Published by Springer Nature
- p. 1013-1029
Management of Fecal Incontinence, Constipation, and Rectal Prolapse